ORIGINAL RESEARCH article

Front. Chem.

Sec. Medicinal and Pharmaceutical Chemistry

Volume 13 - 2025 | doi: 10.3389/fchem.2025.1607067

HIF1A acts as target of XiHuang Pill in the treatment of papillary thyroid cancer by regulating dedifferentiation

Provisionally accepted
Xu-Zhe  YuXu-Zhe YuWei-Li  ZhuWei-Li ZhuHua-Chun  QianHua-Chun QianChun-jiang  SunChun-jiang Sun*
  • Shengzhou Hospital of Traditional Chinese Medicine, Shengzhou, China

The final, formatted version of the article will be published soon.

Background: Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer and has shown a rising incidence globally. Despite its generally favorable prognosis, recurrence and therapeutic resistance remain challenges in clinical management. Traditional Chinese Medicine, particularly Xihuang Pill (XHP), has demonstrated promising anticancer potential in various tumors, but its molecular mechanisms in PTC remain unclear. This study aimed to explore the targets of XHP in the treatment of PTC. Methods: The active ingredients of XHP were first obtained, and ingredients and PTC-related targets were identified, followed by enrichment analysis. Protein-protein interaction (PPI) network was constructed to determine the key ingredients and targets, and then molecular docking was conducted. Key targets’ prognostic role, correlation with differentiation, and immune infiltration level were analyzed based on the TCGA data. In vitro experiments were then performed to validate the role of HIF1A. Finally, the association of clinical characteristics with HIF1A was also assessed. Results: Firstly, 132 common targets were associated with XHP and PTC, enriched in MAPK, PI3K-AKT, and HIF-1 signal pathways. Five hub genes (CCND1, ESR1, AKT, HIF-1A, BCL2) and 2 ingredients were found, with a favorable combination between them. AKT1 and HIF1A were upregulated in PTC, and high expressions of them were related to poor prognosis (all P<0.05). Further, only HIF1A was upregulated in the advanced stage of PTC and significantly correlated with the dedifferentiation (all P<0.05). HIF1A upregulation also correlated with the decrease of activated NK cells abundance in PTC (all P<0.05), while NK cell abundance showed positive correlation with differentiation level (P<0.05). HIF1A inhibited differentiation of PTC cells, while XHP suppressed PTC progression and promoted differentiation by downregulating HIF1A. Finally, histopathological type and positive lymph node number correlated with HIF1A expression (all P<0.05). Conclusions: This study systematically elucidated the potential mechanisms by which XHP exerts anti-PTC effects, highlighting that HIF1A is a promising target of XHP in the treatment of PTC by regulating dedifferentiation. These findings provide a scientific basis for the application of XHP in PTC.

Keywords: Papillary thyroid cancer, Xihuang pill, HIF1A, protein-protein interaction, TCGA

Received: 07 Apr 2025; Accepted: 26 May 2025.

Copyright: © 2025 Yu, Zhu, Qian and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Chun-jiang Sun, Shengzhou Hospital of Traditional Chinese Medicine, Shengzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.